Sharma A, Marques P, Neuen BL, Fletcher RA, et al. Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab 2023 Oct 26. doi: 10.1111/dom.15340.
PMID: 37881140